Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.71B P/E - EPS this Y -6.80% Ern Qtrly Grth -
Income -497.19M Forward P/E -15.00 EPS next Y -11.50% 50D Avg Chg 1.00%
Sales - PEG 0.79 EPS past 5Y - 200D Avg Chg 13.00%
Dividend N/A Price/Book 4.29 EPS next 5Y -31.80% 52W High Chg -9.00%
Recommedations 1.50 Quick Ratio 17.75 Shares Outstanding 123.78M 52W Low Chg 145.00%
Insider Own 0.50% ROA -20.10% Shares Float 103.35M Beta 0.97
Inst Own 103.86% ROE -29.08% Shares Shorted/Prior 9.71M/11.24M Price 50.25
Gross Margin - Profit Margin - Avg. Volume 621,711 Target Price 149.29
Oper. Margin - Earnings Date Nov 4 Volume 641,409 Change 1.91%
About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc. News
11/12/24 Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
11/07/24 We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
11/06/24 Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight
11/05/24 Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
11/01/24 Should You Consider Investing in Vaxcyte (PCVX)?
09/14/24 Vaxcyte, Inc. (PCVX): Among Hedge Funds’ Top Biotech Stock Picks
09/11/24 Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
09/06/24 Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
09/06/24 Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
09/04/24 Vaxcyte Announces Pricing of $1.3 Billion Public Offering
09/04/24 Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
09/04/24 Company News for Sep 4, 2024
09/03/24 Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market
09/03/24 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
09/03/24 Sector Update: Health Care Stocks Decline Late Afternoon
09/03/24 Heard on the Street: Pfizer Better Watch Out for This Biotech
09/03/24 Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why.
09/03/24 Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
09/03/24 Vaxcyte's shares hit record high after early data on pneumococcal vaccine
09/03/24 Vaxcyte’s “best-case” data for pneumococcal vaccine boost shares
PCVX Chatroom

User Image FreeMoneyandFed Posted - 4 days ago

$pcvx MT newswires just reported that CFO of this small company sold 109k shares worth $686K Or Director of $PH sold shares worth 783K Did we see news notifications like this for Palantirs Alex Karp selling 26 million shares ?? It should have been reported every time he filed with SEC. But nope. $pltr Business media is corrupt $qqq $spy

User Image infiniteM Posted - 4 days ago

$PCVX someome at the company is scheduling regular masseuse visits to their HQ

User Image infiniteM Posted - 5 days ago

$PCVX almost there... sigh...

User Image Sam201 Posted - 1 week ago

$PCVX covered! Thanks!

User Image TickerDD_com Posted - 1 week ago

$PCVX How much is PCVX Shorted? What is Short Interest for PCVX? As of 10-31-2024 https://youtu.be/EHxFjCo3uvs

User Image Sam201 Posted - 1 week ago

$PCVX almost there.

User Image insiderbuyingselling Posted - 2 weeks ago

$PCVX new insider selling: 2366 shares. http://insiderbuyingselling.com/?t=PCVX

User Image insiderbuyingselling Posted - 2 weeks ago

$PCVX new insider selling: 5000 shares. http://insiderbuyingselling.com/?t=PCVX

User Image DonCorleone77 Posted - 2 weeks ago

$PCVX Vaxcyte reports Q3 EPS (83c), consensus ($1.13) Cash, cash equivalents and investments were $3.273B as of September 30 compared to $1.242.9B as of December 31, 2023."We are exceptionally proud of the significant progress we have made across the adult and infant clinical programs for our broad-spectrum, carrier-sparing pneumococcal conjugate vaccine PCV candidates, VAX-31 and VAX-24," said Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte. "We believe the recent topline results for VAX-31 in adults demonstrate its potential as a best-in-class PCV to provide protection against both currently circulating and historically prevalent strains while setting a new standard for immunogenicity. For the adult indication, we look forward to moving VAX-31 into a Phase 3 program and plan to initiate the pivotal non-inferiority study by mid-2025. For the pediatric indication, we anticipate delivering the topline data from the primary immunization series of the VAX-24 Phase 2 study by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025. In addition, we plan to initiate the VAX-31 infant Phase 2 study in the first quarter of 2025, subject to IND application clearance by the end of this year." "On the heels of our positive VAX-31 data, we completed a follow-on equity offering, raising $1.4 billion in net proceeds and further bolstering our balance sheet," said Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. "We are well-positioned to maintain continued positive momentum across our PCV franchise, including the advancement of multiple adult and infant clinical studies and key steps to ensure global manufacturing readiness for the large, well-established pediatric population and the expanding adult market. We also continue to invest in our early-stage pipeline, including candidates targeting Group A Strep and Shigella, which, along with Streptococcus pneumoniae, are among the World Health Organization's top antibiotic-resistant pathogens requiring urgent solutions."

User Image WhisperNumber Posted - 2 weeks ago

$EXAS #earnings after close, the expectation from the WhisperNumber community is $0.17, 38c ahead of analyst estimates. Earnings came in $0.29 ahead of the whisper last quarter. 57% beat rate. Implied move +/-12.7%. https://www.whispernumber.com/wr_alerts.jsp #options #trading $PCVX $BMRN $NBIX

User Image insiderbuyingselling Posted - 2 weeks ago

$PCVX new insider selling: 8000 shares. http://insiderbuyingselling.com/?t=PCVX

User Image Sam201 Posted - 10/29/24

$PCVX finally…

User Image LiveTradePro Posted - 10/24/24

Just updated Stocks recently alerted to subscribers $TSLA $NOW $ARM $PCVX https://livetradepro.com/

User Image insiderbuyingselling Posted - 1 month ago

$PCVX new insider selling: 42000 shares. http://insiderbuyingselling.com/?t=PCVX

User Image swingingtech Posted - 1 month ago

$IWM $FTAI $PCVX $INSM https://wallstreetwaves.com/significant-capital-inflows-observed-in-etfs-focus-on-iwm-ftai-pcvx-and-insm/

User Image insiderbuyingselling Posted - 1 month ago

$PCVX new insider selling: 7098 shares. http://insiderbuyingselling.com/?t=PCVX

User Image nobz18 Posted - 1 month ago

$PCVX 20-30% crash incoming

User Image intratio Posted - 09/26/24

Our predictive algorithm reaches the conclusion the value of this stock has a poor outlook for the near future and predicts a gravely bleak future $PCVX

User Image Sam201 Posted - 09/25/24

$PCVX will cover below 95! It may take sometime though..but will eventually reach to 50ish in a year from now.

User Image intratio Posted - 09/25/24

$PCVX https://www.intratio.com/stock-forecast/PCVX Vaxcyte, Inc. Our network foretells this stock s value will shortly go down with a very negative long-term outlook

User Image intratio Posted - 09/24/24

$PCVX https://www.intratio.com/stock-forecast/PCVX Vaxcyte, Inc. Our mathematical model foretells this company s value has bleak prospects for the foreseeable future and is poised to drop further in the coming weeks

User Image nobz18 Posted - 09/24/24

$PCVX It’s kinda wild how overvalued this is on just old news and they aren’t even profitable. $70s coming again soon

Analyst Ratings
Mizuho Outperform Sep 10, 24
B of A Securities Buy Sep 4, 24
Leerink Partners Outperform Sep 3, 24
Jefferies Buy Sep 3, 24
Needham Buy Sep 3, 24
BTIG Buy Sep 3, 24
Needham Buy Aug 7, 24
Needham Buy Jun 28, 24
Cantor Fitzgerald Overweight Jun 20, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Eydelman Mikhail SVP, GEN COUNSEL & C.. SVP, GEN COUNSEL & CORP SEC Feb 01 Sell 73.72 1,667 122,891 20,710 02/05/24
Eydelman Mikhail SVP, GEN COUNSEL & C.. SVP, GEN COUNSEL & CORP SEC Feb 01 Option 21.41 1,667 35,690 22,377 02/05/24
Wassil Jim CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER Feb 01 Sell 73.73 3,000 221,190 175,935 02/05/24
Wassil Jim CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER Feb 01 Option 2.42 3,000 7,260 178,935 02/05/24
PICKERING GRANT CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 01 Sell 73.79 2,616 193,035 149,978 02/05/24
Lukatch Heath Director Director Jan 29 Sell 67.5 4,000 270,000 5,625 01/31/24
Lukatch Heath Director Director Jan 29 Option 16 4,000 64,000 9,625 01/31/24
PICKERING GRANT CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 29 Sell 66.03 30,000 1,980,900 375,814 01/31/24
PICKERING GRANT CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 29 Option 1.79 30,000 53,700 405,814 01/31/24
PICKERING GRANT CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 23 Sell 63.98 15,000 959,700 375,814 01/25/24
PICKERING GRANT CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 23 Option 0.92 15,000 13,800 390,814 01/25/24
GUGGENHIME ANDREW PRESIDENT AND CFO PRESIDENT AND CFO Jan 18 Option 5.35 8,000 42,800 87,474 01/19/24
GUGGENHIME ANDREW PRESIDENT AND CFO PRESIDENT AND CFO Jan 18 Sell 61.67 8,000 493,360 79,474 01/19/24
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Dec 22 Sell 61.7 15,000 925,500 375,814 12/27/23
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Dec 22 Option 1.04 19,900 20,696 390,814 12/27/23
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Nov 24 Sell 49.21 15,000 738,150 370,914 11/28/23
GUGGENHIME ANDREW President and CFO President and CFO Nov 20 Sell 51.54 8,000 412,320 79,474 11/22/23
GUGGENHIME ANDREW President and CFO President and CFO Nov 20 Option 5.35 8,000 42,800 87,474 11/22/23
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Oct 23 Sell 47.16 15,000 707,400 385,914 10/25/23
GUGGENHIME ANDREW President and CFO President and CFO Oct 18 Sell 46.1 8,000 368,800 79,474 10/20/23
GUGGENHIME ANDREW President and CFO President and CFO Oct 18 Option 5.35 8,000 42,800 87,474 10/20/23
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Sep 25 Sell 52.44 17,618 923,888 156,521 09/27/23
Wassil Jim Chief Operating Offi.. Chief Operating Officer Sep 22 Option 2.42 3,000 7,260 170,935 09/26/23
Wassil Jim Chief Operating Offi.. Chief Operating Officer Sep 01 Sell 53.06 3,000 159,180 170,066 09/06/23
Wassil Jim Chief Operating Offi.. Chief Operating Officer Sep 01 Option 2.42 3,000 7,260 173,066 09/06/23
Wassil Jim Chief Operating Offi.. Chief Operating Officer Dec 23 Option 2.42 105,371 254,998 147,715 12/28/22
Fairman Jeff VP, Research VP, Research Oct 26 Sell 40.00 10,000 400,000 286,227 10/28/22
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Sep 26 Sell 24.99 10,000 249,900 157,830 09/28/22
Wassil Jim Chief Operating Offi.. Chief Operating Officer Sep 19 Option 2.42 2,800 6,776 45,144 09/21/22
Wassil Jim Chief Operating Offi.. Chief Operating Officer Sep 19 Sell 26.33 2,800 73,724 42,344 09/21/22
GUGGENHIME ANDREW President and CFO President and CFO Sep 19 Option 5.35 3,100 16,585 40,638 09/21/22
GUGGENHIME ANDREW President and CFO President and CFO Sep 19 Sell 26.27 3,100 81,437 37,538 09/21/22
GUGGENHIME ANDREW President and CFO President and CFO Aug 25 Option 5.35 36,000 192,600 59,840 08/29/22
GUGGENHIME ANDREW President and CFO President and CFO Aug 25 Sell 28 36,000 1,008,000 42,187 08/29/22
Sauer Paul SVP Process Dev, Man.. SVP Process Dev, Manufacturing Aug 22 Sell 25.9283 3,000 77,785 14,687 08/24/22
GUGGENHIME ANDREW President and CFO President and CFO Aug 18 Option 5.35 3,100 16,585 45,287 08/22/22
GUGGENHIME ANDREW President and CFO President and CFO Aug 18 Sell 25.51 3,100 79,081 42,187 08/22/22
Wassil Jim Chief Operating Offi.. Chief Operating Officer Aug 17 Sell 25.15 2,800 70,420 44,506 08/19/22
Wassil Jim Chief Operating Offi.. Chief Operating Officer Aug 17 Option 2.42 2,800 6,776 47,306 08/19/22
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Aug 15 Sell 25.92 11,000 285,120 672,456 08/17/22
Fairman Jeff VP, Research VP, Research Aug 04 Sell 25.6 15,000 384,000 306,227 08/05/22
Sauer Paul SVP Process Dev, Man.. SVP Process Dev, Manufacturing Jul 27 Sell 25.00 3,000 75,000 17,687 07/29/22
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Jul 26 Sell 23.27 10,000 232,700 167,830 07/28/22
Sauer Paul SVP Process Dev, Man.. SVP Process Dev, Manufacturing Jul 20 Sell 25.00 3,000 75,000 20,687 07/22/22
GUGGENHIME ANDREW President and CFO President and CFO Jul 18 Option 5.35 3,100 16,585 45,287 07/20/22
GUGGENHIME ANDREW President and CFO President and CFO Jul 18 Sell 24.77 3,100 76,787 42,187 07/20/22
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Jul 15 Sell 24.61 11,000 270,710 683,456 07/19/22
GUGGENHIME ANDREW President and CFO President and CFO Jul 08 Option 5.35 3,100 16,585 45,287 07/12/22
GUGGENHIME ANDREW President and CFO President and CFO Jul 08 Sell 24 3,100 74,400 42,187 07/12/22
PICKERING GRANT Chief Executive Offi.. Chief Executive Officer Jun 24 Sell 21.01 10,747 225,794 345,660 06/28/22